KMT2A and acute myeloid leukemia: Finally, the following interesting, randomized phase III clinical trial will compare revumenib plus VEN-AZA with placebo plus VEN-AZA in NPM1-mutated or KMT2A-rearranged AML patients (NCT06652438).